Eli Lilly reported a blowout third quarter with $17.6 billion in revenue, driven by tirzepatide sales that topped $10.1 billion across diabetes and obesity brands (Mounjaro and Zepbound). Management raised guidance as tirzepatide became the company’s blockbuster growth engine, outpacing previous market leaders. Lilly said the drug’s uptake across diabetes and weight‑management indications continues to accelerate and is reshaping competitive dynamics in incretin therapies. The company also announced strategic moves to scale manufacturing for oral and injectable GLP‑1/GIP franchise products. Tirzepatide’s performance is prompting rival activity and distribution deals to broaden patient access; the result is increased M&A and partnership interest across the metabolic drug space.